Manufacturing Commercial-Stage Psychedelic Medicines to Treat Serious Mental Health Conditions

Optimi Health Corp. (Nasdaq: OPTH) is a commercial-stage psychedelic drug manufacturer producing finished-dose psilocybin and MDMA capsules for authorized clinics, pharmacies, and clinical trial sponsors around the world.

LATEST NEWS

Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder


5 Reasons Investors Are Watching Optimi Health Corp.

Commercial-Stage Revenue Model: unlike clinical-stage peers, Optimi already recognizes revenue from drug product sales through Australia's Therapeutic Goods Administration Authorized Prescriber Scheme, supplying finished-dose psilocybin and MDMA capsules directly to clinics without distributor middlemen.

GMP-Compliant Manufacturing Licences: Health Canada Drug Establishment Licence, Dealer's Licence, and Precursor Licence authorize commercial manufacture, packaging, testing, and international export of controlled drug products from two 10,000-square-foot facilities in Princeton, British Columbia.

Multi-Market Regulatory Access: active supply into Canada's Special Access Program and clinical trials, a completed export of psilocybin to the United Kingdom for a planned Phase 2 trial, and planned U.S. commercial access pending federal rescheduling of psilocybin and MDMA.

Diversified Product Line: Natural Psilocybin Extract, MDMA 60 mg and 40 mg capsules, and a Natural Microdose line at 1 mg and 2 mg dosages, positioning Optimi across both clinical and emerging wellness channels.

Recent Nasdaq Uplisting and Capital Raise: Optimi completed an oversubscribed Nasdaq offering of 2,400,000 common shares for gross proceeds of approximately US$15 million, alongside a 1-for-30 reverse share split, with trading under OPTH beginning May 20, 2026.

Identifying The Opportunity

KEY LEVELS

Key Level #1 - $7.44 ( +8.37%)

Key Level #2 - $8.34 (21.43%)

Key Level #3 - $9.32 (35.66%)

Support: $6.19


Optimi Health Corp.



GMP-Compliant Manufacturing Platform


  • Optimi's Health Canada-licensed facility is designed to manufacture finished-dose psilocybin and MDMA capsules under strict GMP compliance, supporting commercial supply without reliance on third-party contract manufacturers.
  • Its integrated manufacturing platform allows new dosage formats to be developed and scaled quickly, enabling efficient expansion of the product line.
  • The Natural Psilocybin Extract and MDMA capsule lines are already supplied commercially in Australia, providing real-world validation of Optimi's manufacturing and distribution model.
  • The same manufacturing platform is being expanded into new formats, including a Natural Microdose line at 1 mg and 2 mg capsule strengths for emerging wellness channels.Additional dosage strengths are also planned to expand the MDMA and psilocybin portfolio.


  • The completed export of psilocybin to the United Kingdom, supporting a planned Phase 2 clinical trial, expands Optimi's reach into new international markets.

Commercial Momentum and Market Expansion


  • Optimi is building a diversified commercial-stage psychedelic drug business across Australia, Canada, and the United Kingdom while working toward planned U.S. market access.
  • The long-term distribution agreement with Mind Medicine Australia validates Optimi's supply model and expands its reach under the Therapeutic Goods Administration's Authorized Prescriber Scheme.
  • The completed export to the United Kingdom strengthens Optimi's international footprint, with U.S. commercial access planned pending federal rescheduling of psilocybin and MDMA.


Positioning for Long-Term Growth

  • Optimi Health Corp. is building a vertically integrated psychedelic drug manufacturing business focused on commercial supply, clinical trial support, and international export.
  • Its partnership with Mind Medicine Australia and its GMP-compliant licences validate its manufacturing platform and support expansion into new markets.
  • The completed export to the United Kingdom and planned U.S. access strengthen Optimi's exposure to a growing global psychedelic medicine market.


Introducing the Leadership Team of Optimi Health Corp. (Nasdaq: OPTH)

Dane Stevens

Chief Executive Officer and Co-Founder, CEO since October 2024

Dane Stevens co-founded Optimi Health Corp. in 2020 and has served as Chief Executive Officer since October 2024. His background spans sourcing, manufacturing, and global distribution, experience he has applied to building Optimi's commercial-stage psychedelic drug manufacturing operations from the ground up.

Jacob Safarik

Chief Financial Officer

Jacob Safarik serves as Chief Financial Officer of Optimi Health Corp. He is a Chartered Professional Accountant with over 16 years of experience in accounting, project finance, and business development.

His expertise supports Optimi's financial operations as the company scales its commercial-stage psychedelic drug manufacturing business.

JJ Wilson

Chairman of the Board

JJ Wilson serves as Chairman of the Board of Optimi Health Corp. He is co-founder of Amer Sports and brings a two-decade record in capital markets and brand building to his role guiding the company's governance and strategic direction.

We get our information from SEC filings and verified public sources.

Stay Ahead. Stay Informed. Stay Profitable.

Subscribe to See What They're Watching

Sources

https://optimi.net/ (Company Site), https://www.sec.gov/ (OPTI SEC Filings), https://www.stocktitan.net/ (Filing Summaries), https://www.prnewswire.com/ (Press Releases), https://www.morningstar.com/ (Financial Data), https://www.marketscreener.com/ (Market Data), https://finance.yahoo.com/ (Stock Data)

Disclaimer

Disclaimer

Stock Research Today is a project of Virtus Media Group LLC and intended solely for entertainment and informational purposes. This website / media webpage is owned, operated and edited by Virtus Media LLC. Any wording found on this website / media webpage or disclaimer referencing “I” or “we” or “our” or “Virtus Media” refers to Virtus Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. By reading our website / media webpage you agree to the terms of this disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investment or brokerage advice or anything of an advisory or consultancy nature and therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment and educational purposes only. At most, this communication should serve as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. Consult your financial, investment and tax advisors to determine what financial and tax strategies may be right for you. Investor protection and other important information is available at https://www.sec.gov/.

By using our service, you agree not to hold our site, its editors, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within or referred to from our website / media webpage. We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data.

This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. That information is only valid at the time it is published, and we do not undertake to update it.

Virtus Media’s business model is to receive financial compensation to promote public companies and to conduct investor relations advertising, marketing and publicly disseminate information, not limited to our websites, email, sms, push notifications, influencers, social media postings, ticker tags, press releases, online interviews, podcasts, videos, audio ads, banner ads, native ads, and responsive ads. This compensation is a major conflict of interest in our ability to be unbiased regarding the subject of our reports and communications. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the parties who hired us, or of the profiled companies. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts.

The third parties paying for our services, the profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to impact share prices, possibly significantly. Frequently companies profiled in our alerts experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases.

We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, Virtus Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors.

Pursuant to an agreement between Optimi Health Corp. and Virtus Media Group LLC, Virtus Media has been hired to publicly disseminate information about ticker $OPTH via digital communications beginning Septmber 17th, 2026 ending September 25th, 2026. Virtus will be paid $75,000 from JRZ Capital